No Detail Found!

Bariatric Surgery and Glucagon-Like Receptor-1 Agonists' Effects on Weight, HbA1c and Cardiovascular Outcomes: A Meta-Analysis

Author(s)
Salah Alghamdi Department of Surgery, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia
Abstract
Introduction: Obesity is a highly prevalent chronic disease and is associated with high morbidity. Bariatric surgery is an effective, durable management. Glucagon-like receptor-1 agonists (GLP-1 agonists) showed high effectiveness in weight management with cardiac and renal benefits. Studies comparing bariatric surgery and GLP-1 agonists are scarce. This metaanalysis aimed to compare the effects of bariatric surgery and GLP-1 agonists on weight, HbA1c, major adverse cardiovascular events (MACE) and heart failure. Methods: We searched PubMed/, Google Scholar, Cochrane Library and Web of Science for relevant articles. We used the keywords bariatric surgery, sleeve gastrectomy, gastric bypass, gastric banding, GLP-1 agonists, twincretins, semaglutide, tirzepatide and liraglutide, MACE, acute coronary syndrome, fatal, myocardial infarction, stroke and nonfatal infarction. Out of the 1142 articles retrieved, 716 remained after duplication removal, 22 full texts were reviewed and 7 full texts were included in the final meta-analysis. Results: Bariatric surgery reduced the BMI more than GLP-1 agonists, Standard mean difference (SMD), -8.23, 95% CI, -11.02-5.45, with no differences regarding the HbA1c, MD, 0.08, 95% CI, -0.45-0.6. however, HbA1c was lower in bariatric surgery after eliminating heterogeneity, MD, -0.35, 95% CI, -0.37--0.32. The MACE was lower in bariatric surgery compared to GLP-1 agonists, odds ratio, 1.50, 95% CI, 1.13-1.98 (the result was similar after eliminating heterogeneity, odds ratio, 1.34, 95% CI, 1.15-1.56) and heart failure was lower in bariatric surgery compared to GLP-1 agonists, odds ratio, 1.87, 95% CI, 1.46-2.40. Conclusion: Bariatric surgery reduced weight, MACE and heart failure more than GLP-1 agonists, with similar effects on the glycated haemoglobin. Further larger clinical trials investigating the best GLP-1 and bariatric surgery in obesity and its comorbidities management.
Publication Details
Page(s) 85-91
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 14, Issue: 11, Year: 2025

Request the full text from PASTIC

Keywords
Weight, Heart failure, Bariatric surgery, GLP-1 Agonists, MACE, HbA1C
References
Alqatari S.G.,July 2025 . .Pharmacologic disruption: how emerging weight loss therapies are challenging bariatric surgery guidelines. ” Medicina, 61(7) : 1292.
.2025 .Obesity and Overweight. Accessed August, : .
Dale K.S. . .Sustainability of lifestyle changes following an intensive lifestyle intervention in insulin resistant adults: follow-up at 2-years. Asia Pacific Journal of Clinical Nutrition, 18(2009) : 114-120.
Dawwas G.K.,Samuels J.M.,Stein C.M.,July C.M. .2025 .Shifting obesity treatment paradigms: trends of glucagon-like peptide1 receptor agonists and bariatric surgery in the United States. , : .
Stenberg E.,Näslund E.,April 2023 . .Major adverse cardiovascular events among patients with type-2 diabetes: a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment. International Journal of Obesity, 47(4) : 251-256.
Lin K. .2024 .Metabolic bariatric surgery in the era of GLP-1 receptor agonists for obesity management. ” JAMA Network Open, 41380(10) : e2441380.
Mainous A.G. .2012 .The American Journal of Gastroenterology. , 365(8) : 1218-1223.
Primomo J.A.,November 2016 .2016 .Decreased access to bariatric care: an analysis of referral practices to bariatric specialists.” Surgery for Obesity and Related Diseases. , 08(9) : 1725-1730.
Messiah S.E. .2025 .Metabolic and bariatric surgery utilization in the era of glucagon-like peptide-1 receptor agonists among adolescents versus adults. The Journal of Pediatrics, 114564 : 114564.
Pipek L.Z.,April 2024 . .Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis. ” Scientific Reports, 14(1) : 9521.
Cotugno M.,April 2015 . .Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation. ” Acta Diabetologica, 52(2) : 331-336.
Dicker D.,June 2024 .2024 .Bariatric metabolic surgery vs glucagon-like peptide-1 receptor agonists and mortality. ” JAMA Network Open, 15392(6) : e2415392.
Sagy Wolff,Y. Wolff .2025 .Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer. ” EClinicalMedicine, 103213 : 103213.
Wu T. .2022 .The comparative effects of metabolic surgery, SGLT2i or GLP-1RA in patients with obesity and type 2 diabetes.” Surgery for Obesity and Related Diseases. , 02(6) : 762-771.
Yong S.,Wang J.,Li J. .2012 .“Remission of insulin resistance in type 2 diabetic patients after gastric bypass surgery or exenatide therapy. ” Obesity Surgery, 22 : 1060-1067.
Valderas J.P. .2016 .GLP-1 receptor agonist therapy induces a greater reduction in glycaemic variability compared to gastric bypass in type 2 diabetic patients. ” Diabetologia, 59 : S331.
Husain M. .2020 .Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. ” Diabetes, Obesity and Metabolism, 22 : 442-451.
Ascandar N. .1960 .Clinical outcomes after hospitalization for acute coronary syndrome in patients treated with semaglutide versus bariatric surgery. ” HCA Healthcare Journal of Medicine, 6(3) : 2689-0216.
Zhang Y. .2025 .The epidemiology, clinical characteristics and burden of heart failure with or without obesity in US patients. ” Current Medical Research and Opinion, August, 2535464 : 1-15.
Haseeb M.,April 2024 .2024 .Semaglutide vs endoscopic sleeve gastroplasty for weight loss. ” JAMA Network Open, 6221(4) : e246221.
0

Citations

0

Downloads

12

Views